多巴丝肼联合普拉克索治疗中晚期帕金森病疗效观察

Observation of Curative Effect of Levodopa and Benserazide Tablets and Pramipexole Combination on the Treatment of the Middle-late Parkinson's Disease

目的:观察多巴丝肼片与普拉克索联各治疗中晚期帕金森病的临床疗效和安全性。方法:87例中晚期帕金森病患者随机分为两组,对照组采用多巴丝肼片治疗,观察组在对照组基础上联用普拉克索片治疗,根据患者病情变化增减用药剂量至病情有效控制后维持剂量给药,疗程3个月。用UPDRS评分量表评分、Hoehn-Yahr分期评价两组的疗效。结果:治疗前两组患者UPDRS评分、Hoehn-Yahr分期比较,差异无统计学意义(P>0.05),治疗后,观察组患者的UPDRSⅡ和Ⅲ、Ⅳ评分、Hoehn-Yahr分期变化明显优于对照组(P<0.05)。结论:多巴丝肼片与普拉克索联合治疗中晚期帕金森病疗效更好,且安全性好,值得推广应用。

Objective： To observe the clinical efficacy and safety of levodopa and benserazide tablets and pramipexole combination in the treatment of the middle late Parkinson’s disease. Methods：87 cases of the middle late Parkinson’s patients were randomly divided into two groups：the controlled group was treated with levodopa and benserazide tablets and the observation group was treated with pramipexole for 3 months, based on levodopa and benserazide tablets treatment. Their dosage increased or decreased according to the patients’ condition change till the illness was effectively controlled. UPDRS rating scale and the Hoehn-Yahr stage were used to evaluate the curative effect of the two groups. Methods：Before the treatment, there was no statistically significant difference （P〉0.05） between the two groups in UPDRS score and Hoehn-Yahr stage nbut, but after it the change of UPDRS Ⅱ and Ⅲ, Ⅳ score and Hoehn-Yahr stage in the observation group was obviously better than that of the controlled group. The difference in point change between the two groups was statistically significant（P〈0.05） . Conclusion：Levodopa and benserazide tablets and pramipexole combination therapy of the middle late Parkinson disease curative effect was better and showed its impressive safety; therefore, it was worth popularization and application .